ERBB2 and neoplasm: By quantifying tumor morphology, texture, and vascular heterogeneity, PA/US radiomic features may assist in: Alerting clinicians to equivocal or borderline HER2 cases, guiding targeted biopsy of regions more likely to reflect HER2 expression, enabling longitudinal tracking of HER2 status during neoadjuvant or metastatic treatment.